Actively Recruiting
LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients
Led by University of Illinois at Chicago · Updated on 2026-01-20
29
Participants Needed
1
Research Sites
89 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Single arm, Simon's two stage pilot study in which patients with Non-Small Cell Lung Cancer (NSCLC) with metastatic disease 2L and beyond will receive OncoChoice-informed chemotherapy following National Cancer Care Network (NCCN) treatment guidelines on dosage and scheduling for NSCLC FDA approved drugs.
CONDITIONS
Official Title
LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at time of consent
- ECOG performance status score of 2 or less
- Histologically confirmed Stage IV NSCLC documented by biopsy
- Received at least one prior systemic therapy for Stage IV NSCLC and candidates for second-line or later chemotherapy
- Patients with Stage III NSCLC who have received at least one systemic therapy may be eligible with principal investigator approval
- Adequate organ function with labs within treatment parameters obtained within 30 days prior to registration
- No cancer treatment received for at least 2 weeks before enrollment
- Candidate for small molecule drug treatment
- Able to provide written informed consent and HIPAA authorization
- Women of childbearing potential must not be pregnant or breastfeeding with negative pregnancy test
- Able to understand and comply with study procedures for entire study duration as determined by physician
You will not qualify if you...
- Active infection requiring systemic therapy within 7 days of enrollment
- Uncontrolled HIV/AIDS or active viral hepatitis (e.g., HBV, HCV)
- Significant toxicity from prior anticancer therapy interfering with safety or efficacy assessment
- ECOG performance status score greater than 2
- Clinically significant lung, heart, or autoimmune disease
- Life expectancy less than 12 weeks
- Prior solid organ or bone marrow transplant
- Antibiotics, live vaccines, or surgery within 4 weeks prior to treatment
- Pregnant or nursing
- Prior or concurrent malignancy that interferes with safety or efficacy assessment
- Mental or medical condition preventing informed consent or participation
- Other major comorbidities as determined by treating provider
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Illinois Cancer Center
Chicago, Illinois, United States, 60612
Actively Recruiting
Research Team
F
Frank Weinberg, MD, PhD
CONTACT
R
Ruihong Yin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here